Research · Metabolic medicine · 6 min read
What Is GLP-1 Therapy?
Semaglutide and tirzepatide have changed weight medicine. The right framing is medical, not cosmetic.
Your decision stage
- 01Research
- 02Comparison
- 03Evaluation
- 04Decision
- 05Ready
Decision tool · 5 min
Weight Reduction Path Finder
If this article is the right read for where you are, the Weight Reduction Path Finder is the right next step. Find the medical, lifestyle or surgical path that fits your goal and timeline.
Quick answer
Key takeaways
- 01Medication without behavioural scaffolding rarely sustains results
- 02Muscle preservation is the unspoken priority
- 03Brand-name and compounded formulations differ in oversight
- 04Plan the taper before the first dose
How GLP-1s work
They mimic incretin hormones, slowing gastric emptying and reducing appetite signalling. Effects compound over a 6–12 month titration window.
What a good program looks like
- 01Baseline labs and body composition
- 02Nutrition support with protein targeting
- 03Resistance training for lean-mass preservation
- 04Defined maintenance and taper plan
Decision tool · 5 min
Weight Reduction Path Finder
Find the medical, lifestyle or surgical path that fits your goal and timeline.
FAQs
Asked often.
Will I regain weight if I stop?
+
Without behavioural scaffolding and a structured taper — most patients regain a meaningful portion. Maintenance is the conversation that matters.
What's commonly misunderstood
Patient misconceptions, clarified.
- 01That GLP-1s are a cosmetic shortcut — they're a metabolic medicine with cardiovascular and gastrointestinal effects
- 02That weight loss equals fat loss — without protein and resistance training, 20–40% of loss can be lean mass
- 03That stopping the drug holds the result — most regain happens without a structured taper and behavioural plan
What patients get wrong
Common mistakes to avoid
- 01Starting without baseline labs, body composition or a clinician-led plan
- 02Sourcing compounded formulations online without prescriber oversight
- 03Skipping protein targets and resistance training during the loss phase
- 04No defined maintenance plan before the first dose is taken
Questions patients forget to ask
The questions that protect your outcome.
- 01What's my lean-mass preservation strategy through the loss phase?
- 02What is the taper and maintenance plan after the target is reached?
- 03What side effects should I expect, and at which titration step?
- 04How does this plan handle plateaus or non-response at 12 weeks?
Decision checklist
Before you commit, verify every one.
- Baseline metabolic, thyroid and lipid panel reviewed
- Protein target and resistance-training plan agreed
- Prescriber identified and accessible for side-effect management
- Brand-name vs compounded decision made with full disclosure
- Taper and maintenance plan written down before dose one
During your consultation
What to actually discuss.
- 01Personal and family history of pancreatitis, thyroid or gallbladder disease
- 02Titration schedule and which step you'll be reviewed at
- 03Nutrition and training scaffolding alongside the medication
- 04Long-term plan: 6 months, 12 months, and beyond
The decision arc
- 01
Research
Understand what the category contains and which paths exist.
- 02
Comparison
Weigh approaches side-by-side and rule out the wrong-fit paths.
- 03
Evaluation
Confirm candidacy and pressure-test your shortlist.
- 04
Decision
Prepare specific questions and de-risk the final commitment.
Personalized Guidance
Where are you in the decision?
AltisPath places you on the arc from exploration to consultation-ready — so the next step is the right one, not just the next available one.
Take the assessment →Decision tool · 5 min
Weight Reduction Path Finder
Decision tools are the primary way patients turn insight into a plan on AltisPath. The Weight Reduction Path Finder produces a personalised report you can take to any provider — privately, before contact.
Continue your journey
The next step, recommended.
Explore your treatment path
Insight is the beginning. A plan is the point.
Move from reading to a personalized report and tailored next steps — privately, on your own time.
Editorial standards
Dermatology content is reviewed by board-certified dermatologists practicing in Pune, Mumbai or Bengaluru.
- 01Drafted by the AltisPath decision-content team
- 02Reviewed by a practicing clinician in the relevant specialty
- 03Cross-checked against current Indian clinical practice
- 04Updated when guidelines or pricing change materially
Medical disclaimer: AltisPath is a treatment decision and guidance platform. This article is educational and is not a substitute for a personal medical consultation. Treatment decisions should be made with a qualified clinician who has reviewed your individual case.